Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

Develops medicines for serious diseases

About Regeneron Pharmaceuticals

Simplify's Rating
Why Regeneron Pharmaceuticals is rated
A-
Rated A on Competitive Edge
Rated B on Growth Potential
Rated A on Rating Differentiation

Industries

Biotechnology

Healthcare

Company Size

10,001+

Company Stage

IPO

Total Funding

$684M

Headquarters

Town of Greenburgh, New York

Founded

1988

Overview

Regeneron Pharmaceuticals develops medicines aimed at treating serious diseases such as cancer, eye diseases, and allergic conditions. The company uses its own technologies and extensive research to create new therapies, often working with academic institutions and other pharmaceutical companies to enhance its efforts. This collaboration helps Regeneron stay updated with scientific advancements. Revenue comes from selling approved medicines and licensing its technologies through partnerships that share development costs and profits. Regeneron focuses on ensuring its products meet safety and efficacy standards, aiming to improve patient outcomes.

šŸ’µ
Funded Recently
Simplify Jobs

Simplify's Take

What believers are saying

  • Growing antibody therapy market offers expansion opportunities for Regeneron.
  • Investment in Truveta's genome project accelerates personalized medicine initiatives.
  • Acquisition of Oxular strengthens Regeneron's position in retinal disorder treatments.

What critics are saying

  • Class action lawsuit may lead to financial liabilities and reputational damage.
  • Truveta investment might not yield expected returns, posing financial risk.
  • Integration challenges with Oxular could affect operational efficiency.

What makes Regeneron Pharmaceuticals unique

  • Regeneron leverages proprietary technologies for innovative therapies in serious diseases.
  • Strategic collaborations enhance Regeneron's research and development capabilities.
  • Regeneron's focus on eye diseases and monoclonal antibodies sets it apart.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$684M

Above

Industry Average

Funded Over

2 Rounds

Post IPO Equity funding comparison data is currently unavailable. We're working to provide this information soon!

Post IPO Equity Funding Comparison Coming Soon

Benefits

Health Insurance

Wellness Program

Paid Vacation

Equity Awards

Annual Bonuses

Flexible Work Hours

Company News

PharmiWeb
Jan 29th, 2025
Antibody Therapy Market To Surge, Expected To Reach Usd 824 Billion By 2033 At A 13.4% Of Cagr

Antibody Therapy MarketThe global antibody therapy market is on a strong growth trajectory, projected to expand at a CAGR of 13.4% from 2023 to 2033. With a valuation of USD 235 billion in 2023, the market is expected to surpass USD 824 billion by the end of the forecast period, driven by advancements in monoclonal antibody therapies and increasing demand for targeted treatments.The growing preference for protein-based, non-chemical treatments has fueled the adoption of monoclonal antibody therapy, particularly for cancer and cell-based diseases. Enhanced research and development efforts, supported by government funding, are further strengthening the effectiveness and accessibility of these treatments. Additionally, the expansion of cancer-specialized hospitals is boosting demand for antibody therapies.The market saw a significant boost during the COVID-19 pandemic, with the FDA approving advanced antibody therapies for treatment, leading to an accelerated CAGR of 18.2% between 2017 and 2022. As immunotherapy and chemotherapy resistance challenges continue, monoclonal antibodies have emerged as a promising alternative due to their high efficacy and reduced side effects.Request a Sample Report Now to get Premium Insights: https://www.futuremarketinsights.com/report-sample#5245502d47422d3134333632Key Takeaways:The antibody therapy market is set to grow from USD 235 billion in 2023 to USD 824 billion by 2033 at a CAGR of 13.4%.Rising cancer prevalence, regulatory approvals, and R&D collaborations are key growth drivers.Monoclonal antibodies offer a promising alternative to traditional chemotherapy, addressing tumor resistance and reducing side effects.Increased demand for targeted therapies and expanded healthcare infrastructure are expected to fuel long-term market growth.Key Growth DriversIncreasing Prevalence of Chronic Diseases The rising incidence of chronic diseases, particularly cancer and autoimmune disorders, is a significant driver for the antibody therapy market. As these conditions become more prevalent, the demand for effective treatment options, such as monoclonal antibodies, increases

PR Newswire
Jan 23rd, 2025
America'S Top 40 High School Scientists To Compete For $1.8 Million In Awards At Prestigious Regeneron Science Talent Search

The Regeneron Science Talent Search Celebrates and Rewards Today's Most Talented Young Minds Driving Innovation and Progress through Scientific ExplorationTARRYTOWN, N.Y. and WASHINGTON, Jan. 23, 2025 /PRNewswire/ --Ā Regeneron Pharmaceuticals, Inc.Ā (NASDAQ: REGN) and Society for ScienceĀ (the Society) today announced the top 40 finalistsĀ in the 2025 Regeneron Science Talent Search (STS), the U.S.'s longest-running and most distinguished science, technology, engineering and math (STEM) competition for high school seniors

Rome Sentinel
Jan 13th, 2025
ATTENTION NASDAQ: REGN INVESTORS: Contact Berger Montague About a Regeneron Pharmaceuticals, Inc. Class Action Lawsuit

ATTENTION NASDAQ: REGN INVESTORS: contact Berger Montague about a Regeneron pharmaceuticals, inc. class action lawsuit.

GeekWire
Jan 13th, 2025
Truveta secures $320M for genome project

Seattle-based health data company Truveta secured $320 million in funding to launch the Truveta Genome Project, aiming to create the largest and most diverse genomic dataset. The investment, from 17 health systems, Illumina, and Regeneron, elevates Truveta's valuation to over $1 billion. Regeneron will sequence exomes of 10 million volunteers. Truveta's total funding is nearly $500 million, with Microsoft as the exclusive cloud provider for the project.

Fierce Biotech
Jan 13th, 2025
JPM25: Regeneron, Illumina and more back Truveta for 10M genome sequencing project

To kick off the project, Regeneron made an upfront strategic investment of $119.5 million into Truveta, while Illumina chipped in $20 million as part of a series C financing.

Business Wire
Jan 11th, 2025
REGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

REGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP announces that Regeneron Pharmaceuticals, Inc. investors with substantial losses have opportunity to lead Class Action lawsuit.

PR Newswire
Jan 8th, 2025
Nation'S Top 300 Teen Scientists Selected For Achievements In Stem Innovation And Leadership In Nation'S Oldest And Most Prestigious High School Competition

Regeneron Science Talent Search Sees Record Number of Applicants; $1.2 Million to be Awarded to Nation's Most Promising Young Scientists and Their SchoolsWASHINGTON, Jan. 8, 2025 /PRNewswire/ -- Society for Science (the Society) today announced the top 300 scholars in the Regeneron Science Talent Search 2025, the nation's oldest and most prestigious science and math competition for high school seniors. The 300 scholars will be awarded $2,000 each and their schools will be awarded $2,000 for each enrolled scholar.The Regeneron Science Talent Search scholars were selected from nearly 2,500 entrants from 795 high schools across 48 states, American Samoa, Guam, Washington, D.C., Puerto Rico and 14 other countries. US citizens living abroad are eligible to apply.Scholars were chosen based on their outstanding research, leadership skills, community involvement, commitment to academics, creativity in asking scientific questions and exceptional promise as STEM leaders demonstrated through the submission of their original, independent research projects, essays and recommendations. The 300 scholars hail from 200 American and international high schools in 33 states, Washington D.C., China, Hong Kong, Malaysia, and Switzerland.The full list of scholars can be viewed here: https://www.societyforscience.org/regeneron-sts/2025-scholars/"Congratulations to the 300 scholars in this year's Regeneron Science Talent Search," said Maya Ajmera, President and CEO, Society for Science and Executive Publisher, Science News. "With a record-breaking number of applications, these exceptional young scientists and engineers represent the best in the nation

Pharmaphorum
Jan 3rd, 2025
Regeneron builds in eye disease tech with Oxular takeover

Oxular is working on the development of novel drug/device combinations for sight-threatening retinal disorders, which is a key area of focus for Regeneron.

MarketBeat
Dec 1st, 2024
Erste Asset Management GmbH Makes New $42.48 Million Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Erste Asset Management GmbH makes new $42.48 million investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

PharmiWeb
Nov 15th, 2024
Dupixent Sbla Accepted For Fda Review For The Treatment Of Chronic Spontaneous Urticaria

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the US suffer from chronic spontaneous urticaria (CSU) that is inadequately controlled by antihistaminesFDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decadeParis and Tarrytown, NY, November 15, 2024. The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 antihistamine treatment. The target action date for the FDA decision is April 18, 2025.The resubmitted sBLA is supported by data from the multi-study LIBERTY-CUPID phase 3 clinical program (Study A, Study B, and Study C) for Dupixent in CSU. The sBLA adds results from Study C, which was conducted in patients with uncontrolled CSU who were on standard-of-care antihistamines. Study C, the second LIBERTY-CUPID pivotal study in biologic-naĆÆve patients, met its primary and key secondary endpoints, confirming results seen in the previous Study A. Results showed Dupixent significantly reduced itch and urticaria activity (itch and hives).Safety results in all LIBERTY-CUPID phase 3 studies were generally consistent with the known safety profile of Dupixent in its approved indications

PharmiWeb
Nov 11th, 2024
Astrazeneca And Amgenā€™S Tezspire Meets Both Co-Primary Endpoints In The Phase Iii Waypoint Trial In Patients With Chronic Rhinosinusitis With Nasal Polyps

Tezspire met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps. Tezspire demonstrated a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo. Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that AstraZeneca and Amgenā€™sĀ TezspireĀ (tezepelumab) demonstrated a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo

Recently Posted Jobs

Sign up to get curated job recommendations

Regeneron Pharmaceuticals is Hiring for 0 Jobs on Simplify!

Find jobs on Simplify and start your career today

šŸ’”
We update Regeneron Pharmaceuticals's jobs every 8 hours, so check again soon! Browse all jobs ā†’